StageZero Announces Delisting from the TSX and a Concomitant Application for Listing on the NEX Exchange
(TheNewswire)
TORONTO – TheNewswire - July 25, 2025 -StageZero Life Sciences, Ltd. (the “Company” or “StageZero”) 
SZLS announces that its public listing
on the TSX will be terminated on August 14, 2025 and concomitantly it
is applying to the NEX Exchange (“NEX”) to be publicly listed on NEX.
The NEX is a separate board of the TSX Venture Exchange. The NEXoffers its listed companies support and visibility provided by alisting and trading environment tailored to their needs specificallywhile they are restructuring or financing prior to reactivating theirfull business. Upon reactivation, the Company has the option ofapplying to list on the TSX or the TSX Venture exchanges.
Moving to the NEX offers the following benefits to Shareholders andthe Company:
Continued trading within the prestigious TMX Group of stock exchanges.Trading on NEX takes place on the same fully electronic system as TSXV and is governed by identical trading rules.
Streamlined filing obligations allowing more time for Company to focuson reactivation. Disclosure obligations remain the same.
An ability to raise capital with terms better suited to theCompany’s current growth requirements.
Lower listing costs.
StageZero Life Sciences has been under a Failure to File Cease TradeOrder (“FFCTO”) for thepast 15 months due to a constrained and limited cash flow and the needto finance in order to alleviate this. The Ontario SecuritiesCommission (“OSC“) issued the FFCTO against theCompany on April 9, 2024 for failing to file certain outstandingcontinuous disclosure documents (collectively, the “Documents”) within the timeframes prescribed by applicablesecurities laws.
The Company is pursuing financing opportunities to raise sufficientfunds to pay the significant, outstanding fees to the auditorsand, as a result, allow the Company to return tobeing compliant with the OSC filing requirements. Additionally, afinancing will allow the Company to scale and take full advantage ofthe partner opportunities it has secured, returning it to anticipatedsignificant revenue generation. The Company is working with the OSC,TSX and NEX to effect the listing and financing permissions.
“We believe that a NEX listing is where we should be right now as wework to have the FFCTO revoked. Under NEX regulations, the Company hasan expanded set of financing alternatives that better suit its needsand those of the investors it is in discussion with. Additionally, theexpanded timeframes and lower fees really help while we work ongetting the financing closed and the partnerships launched so we cangrow revenue again” said James Howard-Tripp, Chairman and CEO ofStageZero Life Sciences.
The Company has spent the last 18 months diligently working to reduceoverhead, streamline operations, and build partnerships that willstrength the revenue funnel. A lack of financing has significantlyimpacted and delayed the Company’s growth.That said, the Company now has a very streamlined operation and isscaling in the partnered opportunities with Aristotle, AVRT and theCareOncology Protocol.
The Company intends to use the proceeds of the Proposed Financing to(i) pay fees to its current and former auditors, accountants and otherservice providers, as well as audit, accounting, legal and filing feesto be incurred in preparing and filing all outstanding Documents, (ii)fulfill its operational and contractual commitments, and (iii) satisfyits operating expenses to ensure the continuity of the Company’s business during such time. The Company reasonablybelieves that the proceeds from the Proposed Financing will besufficient to bring its continuous disclosure obligations up to dateand pay all related outstanding fees and provide it with sufficientworking capital to meet its obligations and continue its businessduring such period.
About StageZero Life Sciences,Ltd.
StageZero Life Sciences, Ltd. is a verticallyintegrated healthcare company dedicated to improving the earlydetection and management of cancer and other chronic diseases throughnext-generation diagnostics and unique telehealth programs thatprovide clinical interventions to assist patients who currently havecancer (COC Protocol) as well as help patients reduce the risk ofdeveloping late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is thefirst ever mRNA multi-cancer panel for simultaneously screening formultiple cancers from a single sample of blood with high sensitivityand specificity for each cancer. Aristotle® uses mRNA technology toidentify the molecular signatures of multiple cancer types and isbuilt on the Company's patented technology platform, the SentinelPrinciple. The Sentinel Principle has been validated in more than9,000 patients and used by more than 100,000 patients in NorthAmerica.
The Care Oncology Clinic offers a supervised treatmentregimen (the COC Protocol) for people diagnosed with cancer of anytype or stage. Developed by scientists and oncologists, the COCProtocol is intended for adjunctive administration alongsidestandard-of-care cancer therapy.
Aristotle®, as well as additional cancer diagnosticsare processed at the Company's clinical laboratory, StageZero LifeSciences, Inc. in Richmond, Virginia.
SOURCE StageZero Life Science, Ltd.
Stay Connected
For more information about StageZero, visit www.StageZerolifesciences.com,
For further information pleasecontact:
InvestorRelations
RebeccaGreco
rgreco@stagezerols.com
Cautionary Note Regarding Forward-Looking Information andStatements
This news releasecontains “forward-looking information” within the meaning of applicablesecurities laws. Forward-looking information contained in this pressrelease may be identified by the use of words such as,“may”, “would”, “could”, “will”,“likely”, “expect”, “anticipate”, “believe, “intend”,“plan”, “forecast”, “project”, “estimate”, “outlook” and othersimilar expressions, and includes statements concerning theCompany’sintent to conduct the Proposed Financing, its belief that the proceedswill be sufficient to pay to bring its continuous disclosure record upto date, and its intent to file for a full revocation of the FFCTO,reinstatement of trading on the TSX, the ability to obtain thenecessary approvals in connection with the Proposed Financing, andwith respect to the timing for the filing of the Documents.Forward-looking information is not a guarantee of future performanceand is based upon a number of estimates and assumptions of managementin light of management’s experience and perception of trends,current conditions and expected developments, as well as other factorsrelevant in the circumstances, including assumptions in respect ofcurrent and future market conditions, the current and futureregulatory environment; and the availability of licenses, approvalsand permits. Although the Company believes that the expectations andassumptions on which such forward looking information is based arereasonable, undue reliance should not be placed on the forward lookinginformation because the Company can give no assurance that they willprove to be correct. Actual results and developments may differmaterially from those contemplated by these statements.Forward-looking information is subject to a variety of risks anduncertainties that could cause actual events or results to differmaterially from those projected in the forward-looking information.Such risks and uncertainties include, but are not limited to currentand future market conditions, including the market price of the commonshares of the Company, and the risk factors set out in theCompany’sannual information form dated March 31, 2023 filed with the Canadiansecurities regulators and available under theCompany’sprofile on SEDAR at www.sedar.com . The statements in this pressrelease are made as of the date of this release. The Company disclaimsany intent or obligation to update any forward-looking information,whether as a result of new information, future events or results orotherwise, other than as required by applicable securitieslaws.
Copyright (c) 2025 TheNewswire - All rights reserved.
